As an effective inflammatory mediator of TNF-α or endotoxin (LPS), HMGB1 may progressively exacerbate the inflammation and damage of the bile duct, intrahepatic cholestasis, and hyperbilirubinemia during the early stages of ACLF. This evidence concerns the gene HMGB1 and intrahepatic cholestasis.